The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and ...

The drugmaker has joined an exclusive club primarily populated by technology giants, marking a significant achievement for the healthcare sector. Eli Lilly’s stock has surged more than 35% this year, ...

Eli Lilly’s weight-loss drugs have made it the first pharma company to hit a $1tn market valuation, a sharp turnaround from ...

Eli Lilly’s stock reached an all-time high of 1057.42 USD, marking a significant milestone for the pharmaceutical giant with a market capitalization now exceeding $940 billion. Over the past year, the ...

US stocks turned higher Friday after a week of turbulence amid rising optimism for a December interest-rate cut, while bitcoin kept tumbling as AI worries continued to weigh on investors. While stocks ...

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo ...

Johnson & Johnson entered into a definitive agreement to acquire Halda Therapeutics OpCo for $3.05 billion in cash. Eli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a ...